Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Pfizer Inc. has high expectations for its neuropathic pain blockbuster Lyrica (pregabalin) in China with its initial indication for post-herpetic neuralgia (PHN), but patient education will be key as neuropathic pain is not widely known within China